Інформація призначена тільки для фахівців сфери охорони здоров'я, осіб,
які мають вищу або середню спеціальну медичну освіту.


Підтвердіть, що Ви є фахівцем у сфері охорони здоров'я.

 

International journal of endocrinology Том 14, №3, 2018

Back to issue

Comments on the 2018 European Thyroid Association Guidelines for the management of amiodarone-associated thyroid dysfunction

Authors: Булдигіна Ю.В.(1), Терехова Г.М.(1), Паньків В.І.(2)
(1) — ДУ «Інститут ендокринології та обміну речовин ім. В.П. Комісаренка НАМН України», м. Київ, Україна
(2) — Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України», м. Київ, Україна

Categories: Endocrinology

Sections: Specialist manual

print version


Summary

У цій статті автори виклали й прокоментували основні положення нових рекомендацій щодо обстеження й лікування хворих з аміодарон-асоційованою патологією щитоподібної залози. Їх текст розбитий тематично на підрозділи (клінічні дослідження, діагностика, підходи до корекції). При цьому спочатку йде текст з літературними посиланнями, що підводить до рекомендацій, які викладені за рівнем доказовості.

В данной статье авторы изложили и прокомментировали основные положения новых рекомендаций относительно обследования и лечения больных с амиодарон-ассоциированной патологией щитовидной железы. Их текст разбит тематически на подразделы (клинические исследования, диагностика, подходы к коррекции). При этом сначала идет текст с литературными ссылками, который подводит к рекомендациям, изложенным по уровню доказательности.

In this article, the authors described and commented the main provisions of the new guidelines for the examination and treatment of patients with amiodarone-associated thyroid dysfunction. Their text is divided thematically into subdivisions (clinical studies, diagnosis, approaches to the management). At the same time, the text with references is presented first that followed by guidelines, which are given according to the level of evidence.


Keywords

щитоподібна залоза; аміодарон; рекомендації

щитовидная железа; амиодарон; рекомендации

thyroid gland; amiodarone; guidelines


For the full article you need to subscribe to the magazine.


Bibliography

1. Bogazzi F., Bartalena L., Martino E. Approach to the patient with amiodarone-induced thyrotoxicosis // J Clin Endocrinol Metab. 2010; 95: 2529-2535.
2. Martino E., Bartalena L., Bogazzi F., Braverman L.E. The effects of amiodarone on the thyroid // Endocr Rev. 2001; 22: 240-254.
3. Tanda M.L., Piantanida E., Lai A., Liparulo L., Sassi L., Bogazzi F., Wiersinga W.M., Braverman L.E., Braverman L.E., Martino E., Bartalena L. Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists // Clin Endocrinol (Oxf). 2008; 69: 812-818.
4. Raghavan R.P., Taylor P.N., Bhake R., Vaidya B., Martino E., Bartalena L., Dayan C.M., Bradley K. Amiodarone-induced thyrotoxicosis: an overview of UK management // Clin Endocrinol (Oxf). 2012; 77: 936-937.
5. Ahmed S., Van Gelder I.C., Wiesfeld A.C.P., Van Veldhuisen D.J., Links T.P. Determinants and outcome of amiodarone-associated thyroid dysfunction // Clin Endocrinol (Oxf). 2011; 75: 388-394.
6. Trip M.D., Wiersinga W., Plomp T.A. Incidence, predicta–bility, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism // Am J Med. 1991; 91: 507-511.
7. Swiglo B.A., Murad M.H., Schunemann H.J., Kunz R., Vigersky R.A., Guyatt G.H., Montori V.M. A case for clarity, consistency and helpfulness: State-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system // J Clin Endocrinol Metab. 2008; 93: 666-673.
8. Lambert M.J., Burger A.G., Galeazzi R.L., Engler D. Are selective increases in serum thyroxine (T4) due to iodinated inhibitors of T4 monodeiodination indicative of hyperthyroidism? // J Clin Endocrinol Metab. 1982; 55: 1058-1065.
9. Nademanee K., Singh B.N., Callahan B., Hendrickson J.A., Hershman J.M. Amiodarone, thyroid indexes, and altered thyroid function: long-term serial effects in patients with cardiac arrhythmias // Am J Cardiol. 1986; 58: 981-986.
10. Franklyn J.A., Davis J.R., Gammage M.D., Littler W.A., Ramsden D.B., Sheppard M.C. Amiodarone and thyroid hormone action // Clin Endocrinol (Oxf). 1985; 22: 257-264.
11. Yamazaki K., Mitsuhashi T., Yamada E., Yamada T., Kosaka S., Takano K., Obara T., Sato. Amiodarone reversibly decreases sodium-iodide symporter mRNA expression at therapeutic concentrations and induces antioxidant responses at supraphysiological concentrations in cultured human thyroid follicles // Thyroid. 2007; 17: 1189-1200.
12. Melmed S., Nademanee K., Reed A.W., Hendrickson J.A., Singh B.N., Hershman J.M. Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone admi–nistration // J Clin Endocrinol Metab. 1981; 53: 997-1001.
13. Hershman J.M., Nademanee K., Sugawara M., Peka–ry A.E., Ross R., Singh B.N., DiStefano J.J. 3rd. Thyroxine and triiodothyronine kinetics in cardiac patients taking amiodarone // Acta Endocrinol (Copenh). 1986; 111: 193-199.
14. Amico J.A., Richardson V., Alpert B., Klein I. Clinical and chemical assessment of thyroid function during therapy with amiodarone // Arch Intern Med. 1984; 144: 487-490.
15. Unger J., Lambert M., Jonckheer M.H., Denayer P. Amio–darone and the thyroid: pharmacological, toxic and therapeutic effects // J Intern Med. 1993; 233: 435-443.
16. Wiersinga W.M., Trip M.D. Amiodarone and thyroid hormone metabolism // Postgrad Med J. 1986; 62: 909-914.
17. Batcher E.L., Tang X.C., Singh B.N., Singh S.N., Reda D.J., Hershman J.M. SAFE-T Investigators: Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation // Am J Med. 2007; 120: 880-885.
18. Zhong B., Wang Y., Zhang G., Wang Z. Environmental iodine content, female sex and age are associated with new-onset amiodarone-induced hypothyroidism: a systematic review and meta-analysis of adverse reactions of amiodarone on the thyroid // Cardiology. 2016; 134: 366-371.
19. Bogazzi F., Tomisti L., Bartalena L., Aghini-Lombardi F., Martino E. Amiodarone and the thyroid: a 2012 update // J Endocrinol Invest. 2012; 35: 340-348.
20. Harjai K., Licata A. Effects of Amiodarone on thyroid function // Ann Intern Med. 1997; 126: 63-73.
21. Stott D.J., Rodondi N., Kearney P.M., Ford I., Westendorp R.G.J., Mooijaart S.P., Sattar N., Aubert C.E., Aujesky D., Bauer D.C., Baumgartner C., Blum M.R., Browne J.P., Byrne S., Collet T.H., Dekkers O.M., den Elzen W.P.J., DuPuy R.S., Ellis G., Feller M., Floriani C., Hendry K., Hurley C., Jukema J.W., Kean S., Kelly M., Krebs D., Langhorne P., McCarthy G., McCarthy V., McConnachie A., McDade M., Messow M., O’Flynn A., O’Riordan D., Poortvliet R.K.E., Quinn T.J., Russell A., Sinnott C., Smit J.W.A., Van Dorland H.A., Walsh K.A., Walsh E.K., Watt T., Wilson R., Gussekloo J. TRUST Study Group: Thyroid hormone therapy for older adults with subclinical hypothyroidism // N Engl J Med. 2017; 376: 2534-2544.
22. Benjamens S., Dullaart R.P.F., Sluiter W.J., Rienstra M., van Gelder I.C., Links T.P. The clinical value of regular thyroid function tests during amiodarone treatment // Eur J Endocrinol. 2017; 177: 9-14.
23. Bartalena L., Bogazzi F., Braverman L.E., Martino E. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment // J Endocrinol Invest. 2001; 24: 116-130.
24. Theodoraki A., Vanderpump M.P.J. Thyrotoxicosis associated with the use of amiodarone: the utility of ultrasound in patient management // Clin Endocrinol (Oxf). 2016; 84: 172-176.
25. Bogazzi F., Bartalena L., Dell’Unto E., Tomisti L., Rossi G., Pepe P., Tanda M.L., Grasso L., Macchia E., Aghini-Lombardi F., Pinchera A., Martino E. Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy // Clin Endocrinol (Oxf). 2007; 67: 533-537.
26. Balzano S., Sau F., Bartalena L., Ruscazio M., Balestrie–ri A., Cherchi A., Martino E. Diagnosis of amiodarone-iodine-induced thyrotoxicosis (AIIT) associated with severe nonthyroidal illness // J Endocrinol Invest. 1987; 10: 589-591.
27. Tomisti L., Urbani C., Rossi G., Latrofa F., Sardella C., Manetti L., Lupi I., Marcocci C., Bartalena L., Curzio O., Martino E., Bogazzi F. The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis // J Endocrinol Invest. 2016; 39: 585-591.
28. Piga M., Cocco M.C., Serra A., Boi F., Loy M., Mariot–ti S. The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis // Eur J Endocrinol. 2008; 159: 423-429.
29. Pattison D.A., Westcott J., Lichtenstein M., Toh H.B., Gunawardana D., Better N., Forehan S., Sivaratnam D. Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis // Nucl Med Commun. 2015; 36: 356-362.
30. Loy M., Perra E., Melis A., Cianchetti M.E., Piga M., Serra A., Pinna G., Mariotti S. Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis // Acta Radiol. 2007; 48: 628-634.
31. Yiu K.H., Jim M.H., Siu C.W., Lee C.H., Yuen M., Mok M., Shea Y.F., Fan K., Tse H.F., Chow W.H. Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome // J Clin Endocrinol Metab. 2009; 94: 109-114.
32. O’Sullivan A.J., Lewis M., Diamond T. Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality // Eur J Endocrinol. 2006; 154: 533-536.
33. Wang T.J., Evans J.C., Benjamin E.J., Levy D., LeRoy E.C., Vasan R.S. Natural history of asymptomatic left ventricular systolic dysfunction in the community // Circulation. 2003; 108: 977-982.
34. Tomisti L., Del Re M., Bartalena L., Tanda M.L., Pucci A., Pambianco M., Danesi R., Braverman L.E., Martino E., Bogazzi F. Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature // Endocr Pract. 2013; 19: 1043-1049.
35. Tomisti L., Materazzi G., Bartalena L., Rossi G., Marchello A., Moretti M., De Napoli L., Mariotti R., Miccoli P., Martino E., Bogazzi F. Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction // J Clin Endocrinol Metab. 2012; 97: 3515-3521.
36. Pierret C., Tourtier J.P., Pons Y., Merat S., Duverger V., Perrier E. Total thyroidectomy for amiodarone-associated thyrotoxicosis: should surgery always be delayed for pre-operative medi–cal preparation? // J Laryngol Otol. 2012; 126: 701-705.
37. Kaderli R.M., Fahrner R., Christ E.R., Stettler C., Fuhrer J., Martinelli M., Vogt A., Seiler C.A. Total thyroidectomy for amiodarone-induced thyrotoxicosis in the hyperthyroid state // Exp Clin Endocrinol Diabetes. 2016; 124: 45-48.
38. Zhu L., Zainudin S.B., Kaushik M., Khor L.Y., Chng C.L. Plasma exchange in the treatment of thyroid storm se–condary to type II amiodarone-induced thyrotoxicosis // Endocrinol Diabetes Metab Case Rep. 2016; 2016: 160039.
39. Eskes S.A., Endert E., Fliers E., Gerskus R.B., Dullaart R.P., Links T.P., Wiersinga W.M. Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial // J Clin Endocrinol Metab. 2012; 87: 499-506.
40. Uzan L., Guignat L., Meune C., Mouly S., Weber S., Bertagna X., Bertherat J., Thomopoulos P., Duboc D. Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis // Drug Saf. 2006; 29: 231-236.
41. Sato K., Shiga T., Matsuda N., Onoda N., Takano K., Hagiara N., Kasanuki H. Mild and short recurrence of type II amiodarone-induced thyrotoxicosis in three patients receiving amiodarone continuously for more than 10 years // Endocrine J. 2006; 53: 531-538.
42. Bogazzi F., Bartalena L., Tomisti L., Rossi G., Brogioni S., Martino E. Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study // J Clin Endocrinol Metab. 2011; 96: 3374-3380.
43. Eskes S.A., Wiersinga W.M. Amiodarone and thyroid // Best Pract Res Clin Endocrinol Metab. 2009; 23: 735-751.
44. Jabrocka-Hybel A., Bednarczuk T., Bartalena L., Pach D., Ruchała M., Kamiński G., Kostecka-Matyja M., Huba–lewska-Dydejczyk A. Amiodarone and the thyroid // Endokrynol Pol. 2015; 66: 176-186.
45. Bogazzi F., Tomisti L., Rossi G., Dell’Unto E., Pepe P., Bartalena L., Martino E. Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study // J Clin Endocrinol Metab. 2009; 94: 3757-3762.
46. Bogazzi F., Bartalena L., Cosci C., Brogioni S., Dell’Unto E., Grasso L., Aghini-Lombardi F., Rossi G., Pinche–ra A., Braverman L.E., Martino E. Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study // J Clin Endocrinol Metab. 2003; 88: 1999-2002.
47. Dickstein G., Shechner C., Adawi F., Kaplan J., Baron E., Ish-Shalom S. Lithium treatment in amiodarone-induced thyrotoxicosis // Am J Med. 1997; 102: 454-458.
48. Han T.S., Williams G.R., Vanderpump M.P.J. Benzofuran derivatives and the thyroid // Clin Endocrinol (Oxf). 2009; 70: 2-13.
49. Bogazzi F., Bartalena L., Tomisti L., Rossi G., Tanda M.L., Dell’Unto E., Aghini-Lombardi F., Martino E. Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations // J Clin Endocrinol Metab. 2007; 92: 556-562.
50. Vanderpump M.P.J. Use of glucocorticoids in amioda–rone-induced thyrotoxicosis // Nat Rev Endocrinol. 2009; 5: 650-651.
51. Albino C.C., Paz-Filho G., Graf H. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amio–darone-induced thyrotoxicosis (AIT) // Clin Endocrinol (Oxf). 2009; 70: 810-811.
52. Bogazzi F., Tomisti L., Ceccarelli C., Martino E. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis: a cautionary note // Clin Endocrinol (Oxf). 2010; 72: 133-134.
53. Houghton S.G., Farley D.R., Brennan M.D., van Heerden J.A., Thompson G.B., Grant C.S. Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experien–ce // World J Surg. 2004; 28: 1083-1087.
54. Gough J., Gough I.R. Total thyroidectomy for amiodarone-associated thyrotoxicosis in patients with severe cardiac di–sease // World J Surg. 2006; 30: 1957-1961.
55. Maqdasy S., Batisse-Lignier M., Auclair C., Desbiez F., Citron B., Thieblot P., Roche B., Lusson J.R., Tauveron I. Amiodarone-induced thyrotoxicosis recurrence after amiodarone reintroduction // Am J Cardiol. 2016; 117: 1112-1116.
56. Ryan L.E., Braverman L.E., Cooper D.S., Ladenson P.W., Kloos R.T. Can amiodarone be restarted after amiodarone-induced thyrotoxicosis? // Thyroid. 2004; 14: 149-153.

Back to issue